Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 3—March 2017
Dispatch

Molecular Evidence of Drug Resistance in Asymptomatic Malaria Infections, Myanmar, 2015

Myat Htut Nyunt, Thinzar Shein, Ni Ni Zaw, Soe Soe Han, Fauzi Muh, Seong-Kyun Lee, Jin-Hee Han, Kyaw Zin Thant, Eun-Taek Han1Comments to Author , and Myat Phone Kyaw1
Author affiliations: Department of Medical Research, Yangon, Myanmar (M.H. Nyunt, T. Shein, N.N. Zaw, S.S. Han, K.Z. Thant, M.P. Kyaw); Kangwon National University, Chuncheon, South Korea (M.H. Nyunt, S.-K. Lee, J.-H. Han, F. Muh, E.-T. Han)

Cite This Article

Abstract

Artemisinin resistance containment in Myanmar was initiated in 2011 after artemisinin-resistant Plasmodium falciparum malaria was reported. Molecular evidence suggests that asymptomatic malaria infections harboring drug resistance genes are present among residents of the Myanmar artemisinin resistance containment zone. This evidence supports efforts to eliminate these hidden infections.

The global burden of malaria has been decreasing in recent years as a result of high levels of control of the spread of infection, and the ultimate goal of malaria elimination by 2030 in all Greater Mekong Subregion countries in Southeast Asia seems attainable (1). However, artemisinin-resistant Plasmodium falciparum malaria has been reported in Cambodia, Thailand, Myanmar, Laos, and Vietnam (2). Chloroquine-resistant P. vivax malaria has also been confirmed in 10 countries, including Myanmar (3), and mutations in the mefloquine-resistance molecular marker (pvmdr1 mutation) and sulfadoxine/pyrimethamine-resistance markers (pvdhps, pvdhfr mutations) have been reported in Myanmar (4).

A containment program for artemisinin-resistant malaria was initiated in 2011 according to the Global Plan for Artemisinin Resistance Containment. Areas where artemisinin resistance was documented were ranked as Tier I under the protocol, whereas areas where resistance was suspected were ranked as Tier II. After Myanmar artemisinin resistance containment (MARC) was initiated, malaria morbidity and mortality rates decreased dramatically, especially in MARC Tier I areas (5). However, there are no reports on the prevalence of asymptomatic infections, which may represent a reservoir of local malaria transmission. In this study, we aimed to determine the prevalence of asymptomatic malaria infection and to analyze drug-resistance markers in asymptomatic P. falciparum and P. vivax infections.

The Study

Figure

Thumbnail of The study site, Shwegyin Township, Myanmar, where molecular evidence of drug resistance in asymptomatic malaria infections was obtained. As of 2014, Myanmar artemisinin resistance containment areas were divided into Tier I (52 townships) and Tier II (all remaining townships).

Figure. The study site, Shwegyin Township, Myanmar, where molecular evidence of drug resistance in asymptomatic malaria infections was obtained. As of 2014, Myanmar artemisinin resistance containment areas were divided into Tier I...

As of 2014, the Tier I area of artemisinin resistance in Myanmar was composed of 52 townships; the remaining regions were designated as Tier II. In January 2015, we conducted a cross-sectional study of one of the Tier I areas of the MARC, Shwegyin Township (22°20′0″N, 95°56′0″E) (Figure; Technical Appendix).

Rapid diagnostic tests (RDTs) (HRP2 and P. vivax–specific pLDH-based RDT, SDFK80; Standard Diagnostics, Gyeonggi-do, South Korea), microscopy, and PCR were used to screen for asymptomatic malaria infection (online Technical Appendix). We examined 1,182 local residents, with a male:female ratio of 4:5 and a median age of 30 years (interquartile range 18–45 years). Among these residents, 549 (46.4%) had a history of malaria infection within the past 5 years. No clinical cases of malaria infection were detected during the survey period. Although we found no RDT-positive cases of malaria infection, we detected 2 P. vivax infections by microscopy, with parasite densities of 580 and 1,200 parasites/µL.

When we performed molecular detection for the 4 common malaria species (online Technical Appendix), the overall rate of asymptomatic malaria infection was 2.4% (28/1,180) and included 4 P. falciparum, 22 P. vivax, and 2 P. malariae infections. Although the overall prevalence of asymptomatic infection in these areas was not high, it was similar to that observed in the Thailand–Myanmar border area during 2013–2014 (6).

In this study, RDT and microscopy missed almost all the asymptomatic infections detected by PCR, indicating that only the molecular method is suitable for the detection of asymptomatic infections. Moreover, the asymptomatic cases were broadly distributed geographically throughout the study area. Most of the infections were in male patients (19/28, 67.8%) and in the working-age group. Neither sex nor occupation was identified as an associated factor for asymptomatic infection (Technical Appendix Table 2).

The established artemisinin-resistance marker K13 (kelch 13 gene) and the associated markers pfarps10 (P. falciparum apicoplast ribosomal protein S10), pffd (P. falciparum ferredoxin), and pfmdr2 (P. falciparum multidrug-resistance protein 2) were analyzed in all asymptomatic P. falciparum cases. Nonsynonymous mutations in the propeller region of K13 were found to be associated with artemisinin resistance and associated delayed clearance of the parasite beyond 72 hours after treatment with artemisinin-based combination therapy (7). A previous study in the same region of patients with uncomplicated P. falciparum malaria indicated that 25.3% carried mutant K13 alleles (8). Markers that showed the underlying genetic background predisposing to the K13 mutant were also reported, including pfarps10, pffd, pfmdr2, and pfcrt. Specific single nucleotide polymorphisms of these genes, such as V127M of pfarps10, D193Y of pffd, and T484I of pfmdr2, were found at a similar prevalence as K13 mutations (9).

Among the 4 asymptomatic P. falciparum infections, 2 isolates showed K13 mutations (C580Y in 1 isolate and P574L in the other). C580Y is a well-known validated mutation, and P574L is a candidate marker for artemisinin resistance. Both mutations were reported only in locations in Southeast Asia where artemisinin resistance has been identified (2). Moreover, we observed the pfarps10 mutation (V127M) in 2 of the cases, the pffd mutation (D195Y) in 3 cases, and the pfmdr2 (T484I) mutation in all 4 isolates (Table; Technical Appendix Table 3). This molecular evidence suggests the presence of artemisinin resistance in asymptomatic isolates and calls for action toward eliminating this parasite reservoir.

Similarly, we analyzed all available drug-resistance molecular markers in P. vivax (10), such as pvcrt (P. vivax chloroquine-resistance transporter), pvdhps (P. vivax dihydropteroate synthase), pvdhfr (P. vivax dihydrofolate reductase), and pvmdr1 (P. vivax multidrug-resistance protein 1), in all P. vivax infections. We conducted analysis by using nested PCR, followed by gene sequencing (Technical Appendix).

Among the 22 asymptomatic P. vivax infections, we were unable to amplify pvcrt-o, pvdhfr, and pvmdr1 in 1 isolate and pvdhps in 2 isolates. A high mutation rate was observed in known drug-resistance markers such as pvcrt-o K10 AAG insert (66.6%, 14/21), pvdhps (100.0%, 20/20), pvdhfr (100.0%, 21/21), and pvmdr1 (100.0%, 21/21) (Table). Asymptomatic isolates in this study showed a higher mutation rate of the pvcrt-o AAG insert than those studied in neighboring countries such as Thailand (11), India (12), and China (10). In the pvmdr1 gene, both Y976F and F1076L mutations were observed in 23.8% of cases and F1076L in 19.0% of cases; these rates were higher than those for China (10) and India (12) but lower than those for Thailand (13,14). Although antifolates are not the recommended antimalarial drugs for treatment of P. vivax, pvdhfr and pvdhps mutation rates were noticeable. This finding indicates that drug pressure in P. vivax malaria contributing to drug resistance also needs to be considered in addition to emphasizing the artemisinin-resistant P. falciparum malaria.

One limitation of this study is the exclusive focus on the local residents in the MARC area, where all available control and prevention measures had already been implemented. Unlike the mobile and migrant population, local residents have not been a top priority for the artemisinin resistance containment program, leading to a niche of hidden infection. Moreover, blood pooling before DNA extraction was used in this study for molecular detection of malaria infection. Although this method is not ultrasensitive, it has a higher sensitivity than RDT and microscopy. The hidden asymptomatic infections and associated molecular markers for drug resistance among the asymptomatic cases detected in this study represent a threat to containment and elimination efforts with regard to drug-resistant parasites.

Conclusions

All countries in the Greater Mekong Subregion have set an ultimate goal of eliminating malaria by 2030. One of the main challenges to achieving this goal is hidden asymptomatic infection, which maintains a reservoir for local transmission of malaria (15). Critically, these asymptomatic infections may carry drug-resistance genes, including genes for artemisinin resistance. Our results indicated that drug-resistant malaria parasites may be spreading, even in the containment areas or (pre-)elimination areas; this issue should, therefore, be addressed at a policy level. Detection and elimination of asymptomatic infections are of vital importance. Our evidence highlights the need for a strategy for eliminating drug-resistant malaria in asymptomatic infections in the containment areas.

Dr. Nyunt is a research scientist in the Department of Medical Research, Republic of the Union of Myanmar, and is currently studying in Kangwon National University, Chuncheon, South Korea. His research interests include drug-resistant malaria and neglected tropical diseases.

Top

Acknowledgments

We thank all participants in this study and local health authority personnel and staff from the Parasitology Research Division and Advanced Molecular Research Center, Department of Medical Research and Kangwon Malaria Research Lab, Kangwon National University, South Korea.

This study was supported by the Korea Association of Health Promotion (2016_02), the National Research Foundation of Korea (NRF) grant funded by the South Korea government (MSIP) (NRF-2014R1A2A1A11052079), and by the Basic Science Research Program through the NRF funded by the Ministry of Science, ICT and Future Planning (2015R1A4A1038666).

Top

References

  1. World Health Organization. Strategy for Malaria Elimination in the Greater Mekong Subregion (2015–2030). WHO Regional Office for the Western Pacific; 2015 [cited 2016 Aug 16]. http://www.wpro.who.int/mvp/documents/strat_mal_elim_gms/en/
  2. World Health Organization. Status report: Artemisinin and artemisinin-based combination therapy resistance. Geneva: The Organization; 2016 [cited 2016 Aug 16]. http://apps.who.int/iris/handle/10665/208820
  3. World Health Organization. World Malaria Report 2015. Geneva: The Organization; 2015 [cited 2016 Aug 16]. http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/
  4. World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. Geneva: The Organization; 2010 [cited 2016 Aug 16]. http://www.who.int/malaria/publications/atoz/9789241500470/en/
  5. Township Health Department. Township Health Profile 2012: Shwegyin Township. Department of Health, Myanmar; 2013.
  6. Baum  E, Sattabongkot  J, Sirichaisinthop  J, Kiattibutr  K, Jain  A, Taghavian  O, et al. Common asymptomatic and submicroscopic malaria infections in Western Thailand revealed in longitudinal molecular and serological studies: a challenge to malaria elimination. Malar J. 2016;15:333. DOIPubMed
  7. Ariey  F, Witkowski  B, Amaratunga  C, Beghain  J, Langlois  AC, Khim  N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:505. DOIPubMed
  8. Ashley  EA, Dhorda  M, Fairhurst  RM, Amaratunga  C, Lim  P, Suon  S, et al.; Tracking Resistance to Artemisinin Collaboration (TRAC). Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:41123. DOIPubMed
  9. Miotto  O, Amato  R, Ashley  EA, MacInnis  B, Almagro-Garcia  J, Amaratunga  C, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet. 2015;47:22634. DOIPubMed
  10. Lu  F, Wang  B, Cao  J, Sattabongkot  J, Zhou  H, Zhu  G, et al. Prevalence of drug resistance-associated gene mutations in Plasmodium vivax in Central China. Korean J Parasitol. 2012;50:37984. DOIPubMed
  11. Lu  F, Lim  CS, Nam  D-H, Kim  K, Lin  K, Kim  T-S, et al. Genetic polymorphism in pvmdr1 and pvcrt-o genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-endemic countries. Acta Trop. 2011;117:6975. DOIPubMed
  12. Ganguly  S, Saha  P, Guha  SK, Das  S, Bera  DK, Biswas  A, et al. In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother. 2013;57:124651. DOIPubMed
  13. Suwanarusk  R, Chavchich  M, Russell  B, Jaidee  A, Chalfein  F, Barends  M, et al. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis. 2008;198:155864. DOIPubMed
  14. Rungsihirunrat  K, Muhamad  P, Chaijaroenkul  W, Kuesap  J, Na-Bangchang  K. Plasmodium vivax drug resistance genes; Pvmdr1 and Pvcrt-o polymorphisms in relation to chloroquine sensitivity from a malaria endemic area of Thailand. Korean J Parasitol. 2015;53:439. DOIPubMed
  15. Okell  LC, Ghani  AC, Lyons  E, Drakeley  CJ. Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis. J Infect Dis. 2009;200:150917. DOIPubMed

Top

Figure
Table

Top

Cite This Article

DOI: 10.3201/eid2303.161363

1These authors contributed equally to this article.

Table of Contents – Volume 23, Number 3—March 2017

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Eun-Taek Han, Department of Medical Environmental Biology and Tropical Medicine, Kangwon National University, Chuncehon-si, Gangwon-do, 200-701, South Korea;

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: February 17, 2017
Page updated: February 17, 2017
Page reviewed: February 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external